» Articles » PMID: 11231448

Impaired Fasting Glucose Concentrations in Nondiabetic Patients with Ischemic Heart Disease: a Marker for a Worse Prognosis

Overview
Journal Am Heart J
Date 2001 Mar 7
PMID 11231448
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The issue of whether glucose concentrations below the diabetic threshold may be predictive of increased cardiovascular risk has not yet been fully elucidated. The current study evaluates the prognosis of nondiabetic patients with ischemic heart disease (IHD) and impaired fasting glucose (IFG) over a 7.7-year follow-up period.

Methods: A total of 11,853 patients with documented coronary artery disease aged between 45 and 74 years were examined. Patients were divided into 3 groups on the basis of their fasting blood glucose levels at screening: nondiabetic individuals, patients with IFG, and undiagnosed diabetic patients. Patients who were on any type of pharmacologic antidiabetic treatment were excluded from the study. Mortality rates were assessed separately for each group.

Results: The population comprised 9773 nondiabetic patients (82.4%, glucose up to 109 mg/dL), 1258 patients with IFG levels (10.6%, glucose 110-125 mg/dL), and 822 diabetic subjects (7%, glucose > or =126 mg/dL). Patients were followed up from 6.2 to 9.0 years (mean follow-up period 7.7 +/- 1.5 years). Crude mortality was lower in the nondiabetic subjects than in the 2 other groups. All-cause mortality in the nondiabetic group was 14.3% compared to 20.1% in patients with IFG and 24.3% in the undiagnosed (P <.001). Multivariate adjustment showed the lowest mortality in nondiabetic subjects, who exhibited a survival rate of 0.86 at the end of the follow-up, whereas the lowest survival-0.75-was seen among undiagnosed diabetic patients (P =.0001). An intermediate value of 0.78 was documented for patients with IFG (P <.01). After multivariate analysis, with nondiabetic patients as the reference group, IFG was identified as a consistent predictor of increased all-cause and IHD mortality with hazard ratios of 1.39 (95% confidence interval 1.21-1.59) and 1.29 (95% confidence interval 1.01-1.64), respectively.

Conclusions: The main finding of this study is the substantially increased mortality rate among nondiabetic coronary patients with IFG, who had fasting glucose levels markedly lower than hitherto acknowledged as defining overt diabetes.

Citing Articles

A new kid in town: Cardiovascular Diabetology-Endocrinology Reports.

Fisman E, Westermeier F, Santulli G Cardiovasc Diabetol. 2025; 24(1):30.

PMID: 39844290 PMC: 11755897. DOI: 10.1186/s12933-025-02602-1.


A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy.

Sun Y, Shu Y, Liu B, Liu P, Wu C, Zheng R Exp Ther Med. 2017; 12(6):4017-4024.

PMID: 28105133 PMC: 5228439. DOI: 10.3892/etm.2016.3871.


Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.

Goldberg R, Bittner V, Dunbar R, Fleg J, Grunberger G, Guyton J Am J Med. 2016; 129(7):753.e13-22.

PMID: 27036394 PMC: 4914402. DOI: 10.1016/j.amjmed.2016.02.039.


Older Age, Higher Body Mass Index and Inflammation Increase the Risk for New-Onset Diabetes and Impaired Glucose Tolerance in Patients on Peritoneal Dialysis.

Dong J, Yang Z, Chen Y Perit Dial Int. 2016; 36(3):277-83.

PMID: 26847585 PMC: 4881790. DOI: 10.3747/pdi.2015.00182.


Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease.

Liu X, Cao J, Fan L, Liu L, Li J, Hu G J Geriatr Cardiol. 2013; 10(1):21-7.

PMID: 23610570 PMC: 3627718. DOI: 10.3969/j.issn.1671-5411.2013.01.005.